Table 6.
Company rankings on overall clinical trial transparency for novel drugs approved in 2015
| Rank No | Company (new drug application sponsor) | Patient trials score (%) | Data sharing score (%) | FDAAA trials score (%) | Overall company score (%) |
|---|---|---|---|---|---|
| 1 | Roche | 100 | 100 | 100 | 100 |
| 1 | NovoNordisk | 100 | 100 | 100 | 100 |
| 3 | Novartis | 98 | 100 | 100 | 99 |
| 4 | Merck | 100 | 80 | 100 | 93 |
| 5 | BMS | 96 | 80 | 100 | 92 |
| 5 | Pfizer | 100 | 75 | 100 | 92 |
| 7 | Gilead | 94 | 80 | 100 | 91 |
| 8 | Janssen/Johnson & Johnson | 85 | 100 | 86 | 90 |
| 9 | AstraZeneca | 86 | 78 | 86 | 83 |
| 10 | Valeant | 76 | 14 | 100 | 63 |
| 11 | Amgen | 46 | 66 | Not applicable | 56 |
| 12 | Allergan | 43 | 59 | 40 | 47 |
| Median (interquartile range) score | 95 (83-100) | 80 (73-100) | 100 (93-100) | 92 (78-95) |
*
Amgen received approval from the Food and Drug Administration for its drug Corlanor based on trials largely completed before FDAAA (FDA Amendments Act) took effect. Therefore, its company score and ranking are based solely on public availability of trials conducted in patients (it does not include a FDAAA score). Additionally, Amgen is the US new drug application sponsor of the drug, but it did not sponsor any of the trials in the new drug application. Corlanor is the subject of a licensing agreement between Amgen and Les Laboratoires Servier, executed in June 2013, for the US registration and commercialization of the drug.